Tech Company Financing Transactions

LimmaTech Biologics Funding Round

LimmaTech Biologics, operating out of Schlieren, scored $37 million in funding from Adjuvant Capital, AXA Investment Managers and Novo Holdings.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

Grabenstrasse 3
Schlieren, 8952
CH

Phone

+41 44 733 8585

Website

www.lmtbio.com

Email Address

[email protected]

Overview

LimmaTech was founded in 2015 as a spin-off from GlycoVaxyn. We are applying our deep expertise in engineering complex carbohydrate molecules to develop next-generation vaccines to prevent life-threatening diseases. Our proprietary pipeline is focused on diseases with emerging antimicrobial resistance (AMR).

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Franz Haas

        

Chief Financial Officer

Paul Wolfrom

        

Co-Founder

Michael Kowarik

        

Browse more venture capital transactions:

Prev: 10/9/2023: Commons Clinic venture capital transaction
Next: 10/9/2023: Jetson venture capital transaction

Share this article

Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary